Policy Developments - The National Health Commission and 13 other departments announced the "Five Health Promotion Action Plan" for children and adolescents, aiming to improve health in areas such as obesity, myopia, psychological behavior abnormalities, spinal deformities, and dental caries by 2026-2030 [2] Drug and Medical Device Approvals - Aosheng Pharmaceutical received approval for the market launch of the raw materials for Palbociclib and Dapagliflozin, which will enhance the company's product line and competitiveness [4] - Aied Biological obtained a medical device registration certificate for its BRCA1/BRCA2 gene mutation detection kit for prostate cancer, marking the first approval for this indication in China [5] Capital Markets - Yingsi Intelligent successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 2.277 billion, becoming the first AI-driven biopharmaceutical company to list under the main board rules [7] - China Pharmaceutical announced a plan to acquire 70% of Shanghai Zezheng Pharmaceutical for RMB 525 million, focusing on improved drug development services [8] - Yuekang Pharmaceutical submitted an application for H-share issuance to the Hong Kong Stock Exchange [9] Industry Events - Guangdong Province will implement a "one registration for three days" policy in public medical institutions starting January 1, 2026, allowing patients to return for follow-up consultations without additional registration fees within three days [11] Company Developments - Jincheng Pharmaceutical signed a supplementary agreement regarding tax payment responsibilities with shareholders, clarifying compensation terms related to tax liabilities [12] - *ST Chang Pharmaceutical faced a court ruling rejecting its restructuring application, leading to the bankruptcy of its subsidiary and potential delisting risks due to financial misconduct investigations [14]

Core Viewpoint - *ST Changyao is facing multiple delisting risks due to its stock price falling below par value, suspected financial data falsification, and an expected negative net asset at the end of the period, which has attracted significant market attention [1] Group 1: Stock Price and Listing Rules - On December 30, 2025, *ST Changyao's stock closed at 0.95 yuan per share, marking the first instance of the closing price falling below 1 yuan [3] - According to the Shenzhen Stock Exchange's listing rules, if the stock price remains below 1 yuan for twenty consecutive trading days, it will face delisting [3] - The company is required to issue a risk warning announcement the day after the first occurrence of the stock price falling below 1 yuan and must continue to disclose risks if the situation persists [3] Group 2: Regulatory Investigations and Financial Irregularities - On November 7, 2025, *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected financial data falsification [3] - The CSRC issued a prior notice of administrative penalty on December 26, 2025, indicating that the company had inflated its revenue by 215 million yuan, 284 million yuan, and 234 million yuan for the years 2021, 2022, and 2023, respectively [4] - The inflated profits for the same years were reported as 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [4] Group 3: Financial Condition and Risks - As of the end of 2024, the audited net assets attributable to shareholders were -433 million yuan, leading to a delisting risk warning [5] - By the end of the third quarter of 2025, the net assets further declined to -643 million yuan, with an expectation of negative net assets by December 31, 2025, which could trigger financial delisting conditions [5] - The company is involved in 152 litigation and arbitration cases, with a total amount of 1.932 billion yuan, which is 446% of the latest audited net assets [5] - The company has significant interest-bearing debts of 1.106 billion yuan, with overdue debts amounting to 390 million yuan, impacting its repayment capacity [5]

Core Viewpoint - *ST Changyao's stock price has fallen below 1 yuan for the first time, potentially leading to delisting due to continuous trading below this threshold and ongoing investigations by the China Securities Regulatory Commission (CSRC) for financial misconduct [2][4][6] Financial Performance - The company reported a negative net asset value of -433 million yuan for the end of 2024, which could trigger mandatory delisting if the negative trend continues into 2025 [5] - The audited net profits for 2022, 2023, and 2024 were -76.39 million yuan, -632 million yuan, and -569 million yuan respectively, indicating a consistent decline in financial performance [5] Legal and Regulatory Issues - The CSRC has identified that *ST Changyao inflated revenue and profits for three consecutive years, leading to proposed fines of 10 million yuan for the company and 31 million yuan for 14 responsible individuals [6] - The company is under investigation for potential major violations that could result in delisting, with the Shenzhen Stock Exchange initiating delisting procedures [6] Court Proceedings - The company faced a court ruling that rejected its restructuring application, indicating a lack of feasibility for reorganization [3] - The court also terminated the substantive merger restructuring process for *ST Changyao and six other companies, declaring them bankrupt [3]

在相继披露了法院裁定不予受理重整申请暨子公司宣告破产、公司股票可能被实施重大违法强制退市相关风险、公司股票被叠加实施退市风险警示的公告 后，*ST长药（300391）的股价在12月30日盘中一度跌停，当天收盘价报0.95元/股，下跌19.49%。 30日晚间，*ST长药发布公告，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1元而被终止上市。同时，公司因涉嫌定期报告等 财务数据虚假记载被证监会立案调查，可能触及重大违法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实 施财务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税风险。 对于股价跌破1元、法院裁定不予受理重整申请的影响，以及后续措施等，上证报记者以投资者身份致电*ST长药投资者专线，公司相关人士回应："不出 意外是要退市，暂无应对措施。" 在涉嫌触及重大违法强制退市情形前，*ST长药已存在财务类强制退市风险。 同时，据公司2022年、2023年、2024年年度报告，公司2022年、2023年、2024年度经审计的扣除非经常性损益后的净利润分别为-763 ...

人民财讯12月30日电，*ST长药（300391）12月30日公告，12月30日，公司股票收盘价格为0.95元/股， 根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规定，若公司出现连续二十个交易日的股票 收盘价均低于1元，公司股票将被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会 立案调查，可能触及重大违法强制退市情形；公司2024年度期末净资产为负，若2025年度期末净资产继 续为负，将被实施财务类强制退市。此外，公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险， 账户冻结风险以及大额欠税风险。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 *ST长药(300391.SZ)公告称，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1 元而被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会立案调查，可能触及重大违 法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实施财 务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税 风险。 ...

*ST长药(300391.SZ)公告称，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1 元而被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会立案调查，可能触及重大违 法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实施财 务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税 风险。 ...

证券代码：300391 证券简称：*ST长药 公告编号：2025-108 长江医药控股股份有限公司 关于公司股票存在可能因股价低于面值被终止上市的 风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、2025年12月30日，长江医药控股股份有限公司（以下简称"公司"或" 长药控股"）股票收盘价格为0.95元/股，根据《深圳证券交易所创业板股票上 市规则》第10.2.3条的规定，上市公司首次出现股票收盘价格低于1元情形的， 应当在次一交易日披露公司股票可能被终止上市的风险提示公告。根据《深圳 证券交易所创业板股票上市规则》第10.2.1条的规定，若公司出现连续二十个 交易日的股票收盘价均低于1元，公司股票将被终止上市。 2、公司因涉嫌定期报告等财务数据虚假记载，被中国证券监督管理委员会 （以下简称"中国证监会"）立案调查。公司及相关人员于2025年12月26日收 到中国证监会下发的《行政处罚事先告知书》（以下简称"《告知书》"）。 根据《告知书》认定的事实，公司2021年、2022年、2023年年度报告存在虚假 记载，公司可能触及《深圳证 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-109 长江医药控股股份有限公司 股票交易严重异常波动的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"或"长药控股"）股票于2025 年12月29日、2025年12月30日连续2个交易日内日收盘价格跌幅偏离值累计 -35.30%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波 动的情形；公司股票连续25个交易日内日收盘价格跌幅偏离值累计-70.84%，根 据《深圳证券交易所交易规则》的相关规定，属于股票交易严重异常波动的情形。 敬请广大投资者注意投资风险。 二、公司关注并核实情况说明 针对本次公司股票交易异常波动，公司董事会就相关事项进行了核实与自查， 具体情况如下： 1、公司前期披露的信息目前不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、经查询、问询，公司、控股股东和实际控制人不存在关于公司的应披露 而未披露的重大事项或处于筹划阶段的重大事项。 4、经问 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]